Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era
| Autor: | Rafael Fuentes-Raspall, Silvia Guerra-Prio, Montserrat Puig-Vives, Rafael Marcos-Gragera, Ferran Perez-Bueno |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Cancer Research Pathology medicine.medical_specialty Epidemiology Population Central nervous system Central Nervous System Neoplasms medicine Temozolomide Humans education Antineoplastic Agents Alkylating education.field_of_study business.industry Population based survival Middle Aged medicine.disease Prognosis Survival Analysis Cancer registry Dacarbazine medicine.anatomical_structure Oncology Spain Population study Choroid plexus Female business medicine.drug Glioblastoma |
| Zdroj: | Cancer epidemiology. 38(3) |
| ISSN: | 1877-783X |
| Popis: | The present population-based study describes the survival of malignant central nervous system (CNS) tumors diagnosed during 15 years. Also, we obtained individual data regarding the use of temozolomide to analyze the impact of this drug on the survival of patients diagnosed with glioblastoma. From 1994 to 2008, a total of 679 incident cases of primary CNS tumors were reported by the Girona Cancer Registry after excluding 39 cases diagnosed by death certificate only. Number of cases and the corresponding proportion for each CNS histological subtype in the study population were: 25 oligodendroglial and oligoastrocytics (3.7%), 22 ependymal tumors (3.2%), 24 embryonal (3.5%), 372 astrocytic (54.8%), 1 choroid plexus (0.1%) and 235 without histological confirmation (34.6%). Observed survival after 5 years since diagnosis for the histological subtype were: 58.8%; 47.5%; 37.0%; 14.5% and 6.5%, respectively (p0.001). Survival of patients diagnosed with glioblastoma according to temozolomide treatment (yes/no) was 60.8% vs. 13.6% and 5.9% vs. 2.5% after 1 and 5 years since diagnosis, respectively. Short-term survival was higher for patients diagnosed with glioblastoma and treated with temozolomide than patients not treated with temozolomide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect